ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo report the efficacy and durability of switching treatment to faricimab in recalcitrant neovascular age-related macular degeneration (nAMD) at six months after completion of the loading phase (nine months after switching).
methodsRecalcitrant nAMD was defined as persistent fluid despite monthly injections (q4w) or inability to extend treatment intervals beyond six weeks (q6w). The study included patients on a treat & extend regimen for six months after three monthly injections. Primary outcomes were changes in central subfield thickness (CST), subfoveal choroidal thickness (SFCT), visual acuity, and injection interval.
resultsNine month-data was available for 56 eyes initially switched to faricimab. At nine months, 51 eyes (91.1%) of 49 patients were maintained on faricimab, while five eyes (8.9%) had been switched back to their older agent. At nine months after switching, median CST was significantly reduced as compared to baseline at switching (332,00 (Q1:295,00; Q3:394,00) to 303,00 (Q1:269,00; Q3:366,00) µm; p < 0.001). Median SFCT also decreased from 158,00 (Q1:116,00; Q3:219,00) µm to 127,00 (Q1:95,00; Q3:196,00) µm (p < 0.001). The average injection interval was significantly extended from 37.0 ± 9.5 days prior to switching to 56.1 ± 30.4 days at nine months (p = 0.002). Visual acuity was maintained (0.30 (Q1:0.10 Q3:0.50) vs. 0.30 (Q1:0.10 Q3:0.50) logMAR; p = 0.07).
conclusionIn recalcitrant nAMD, faricimab can improve CST and SFCT while maintaining visual acuity. Furthermore, greater durability could be achieved with faricimab at nine months as compared to ranibizumab or aflibercept. Further prospective randomized trials are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.